Dyeing to know: The use of vaginal applicator staining and other techniques to assess adherence to product use in microbicide trials

Sexually Transmitted Diseases

Volumn 39, Issue 9, 2012, Pages 713-715

  Mauck, Christine K ^a   Schwartz, Jill L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; PLACEBO; TENOFOVIR;

CLINICAL TRIAL; CONDOM; DEVICES; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONITORING; REVIEW; SELF REPORT; VAGINAL APPLICATOR;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS; COLORING AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; STAINING AND LABELING; VAGINA;

EID: 84865468882     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318264f6b0     Document Type: Review

References (22)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
2. Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: A randomised controlled trial. Lancet 2007; 370:251-261.
3. Weiss HA, Wasserheit JN, Barnabas RV, et al. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 2008; 5:8.
4. Mâsse BR, Boily MC, Dimitrov D, et al. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol 2009; 6:5.
5. Pool R, Montgomery CM, Morar NS, et al. Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangula-tion model. PLoS One 2010; 5:e11632.
6. Turner AN, De Kock AE, Meehan-Ritter A, et al. Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol 2009; 62:759-765.
7. Wallace A, Thorn M, Maguire RA, et al. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis 2004; 8:465-468.
8. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 2007; 76:53-56.
9. Hogarty K, Kasowitz A, Herold BC, et al. Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis 2007; 34:1000-1003.
10. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carra-guard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
11. Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 2009; 36:368-371.
12. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011; 6:e16475.
13. Katzen LL, Fernández-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis 2011; 38:1050-1055.
14. Mensch BS, Hewett PC, Abbott S, et al. Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: An interview mode experiment using a placebo gel. AIDS Behav 2011; 15:407-421.
15. Moench TR, O'hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis 2012; 39:335-340.
16. Schwartz JL, Ballagh SA, Kwok C, et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007; 75:136-141.
17. Friedland B, Abbott S, Sarna A, et al. Does advance knowledge of biomarkers improve adherence and/or the reporting of sexual activity, gel, and condom use among clinical trial participants? Results from a placebo gel trial in Andhra Pradesh, India. Presented at: Microbicides 2012 Conference; April 15, 2012; Sydney, Australia.
18. Olivieri NF, Matsui D, Hermann C, et al. Compliance assessed by the Medication Event Monitoring System. Arch Dis Child 1991; 66:1399-1402.
19. Gengiah et al. The CAPRISA 004 "Wisebag:" Enhancing adherence measurement in microbicides. Presented at: Microbicides 2010 Conference; May 23, 2010; Pittsburgh, PA.
20. van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-F19.
21. Karim SS, Kashuba AD, Werner L, et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet 2011; 378:279-281.
22. Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African women. Presented at: CROI Conference; May 6, 2012; Seattle, WA.